Neurotech International Ltd. (AU:NTI) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Neurotech International Ltd (ASX: NTI) has made substantial strides in FY2024 with its NTI164 cannabinoid drug therapy, meeting key clinical trial endpoints for several paediatric neurological disorders such as Autism Spectrum Disorder and Rett Syndrome. The company successfully raised $10 million to support its endeavors, including manufacturing and potential registration of NTI164, while also expanding its leadership team with the appointment of a new CEO. Neurotech continues to strengthen its patent portfolio and financial position, promising an exciting year ahead for investors.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.